-
Je něco špatně v tomto záznamu ?
Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin
A. Obr, P. Röselová, D. Grebeňová, K. Kuželová,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
Public Library of Science (PLoS)
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2006-12-01
Open Access Digital Library
od 2006-10-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2008-01-01
Nursing & Allied Health Database (ProQuest)
od 2006-12-01
Health & Medicine (ProQuest)
od 2006-12-01
Public Health Database (ProQuest)
od 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
- MeSH
- buněčná adheze účinky léků MeSH
- chronická myeloidní leukemie patologie MeSH
- dasatinib farmakologie MeSH
- fibronektiny metabolismus MeSH
- fosforylace účinky léků MeSH
- imatinib mesylát farmakologie MeSH
- kinetika MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- protinádorové látky farmakologie MeSH
- skupina kinas odvozených od src-genu metabolismus MeSH
- transport proteinů účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000635
- 003
- CZ-PrNML
- 005
- 20200120154727.0
- 007
- ta
- 008
- 160108s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0107367 $2 doi
- 035 __
- $a (PubMed)25198091
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Obr, Adam $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
- 245 10
- $a Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin / $c A. Obr, P. Röselová, D. Grebeňová, K. Kuželová,
- 520 9_
- $a Attachment of stem leukemic cells to the bone marrow extracellular matrix increases their resistance to chemotherapy and contributes to the disease persistence. In chronic myelogenous leukemia (CML), the activity of the fusion BCR-ABL kinase affects adhesion signaling. Using real-time monitoring of microimpedance, we studied in detail the kinetics of interaction of human CML cells (JURL-MK1, MOLM-7) and of control BCR-ABL-negative leukemia cells (HEL, JURKAT) with fibronectin-coated surface. The effect of two clinically used kinase inhibitors, imatinib (a relatively specific c-ABL inhibitor) and dasatinib (dual ABL/SRC family kinase inhibitor), on cell binding to fibronectin is described. Both imatinib and low-dose (several nM) dasatinib reinforced CML cell interaction with fibronectin while no significant change was induced in BCR-ABL-negative cells. On the other hand, clinically relevant doses of dasatinib (100 nM) had almost no effect in CML cells. The efficiency of the inhibitors in blocking the activity of BCR-ABL and SRC-family kinases was assessed from the extent of phosphorylation at autophosphorylation sites. In both CML cell lines, SRC kinases were found to be transactivated by BCR-ABL. In the intracellular context, EC50 for BCR-ABL inhibition was in subnanomolar range for dasatinib and in submicromolar one for imatinib. EC50 for direct inhibition of LYN kinase was found to be about 20 nM for dasatinib and more than 10 µM for imatinib. Cells pretreated with 100 nM dasatinib were still able to bind to fibronectin and SRC kinases are thus not necessary for the formation of cell-matrix contacts. However, a minimal activity of SRC kinases might be required to mediate the increase in cell adhesivity induced by BCR-ABL inhibition. Indeed, active (autophosphorylated) LYN was found to localize in cell adhesive structures which were visualized using interference reflection microscopy.
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a buněčná adheze $x účinky léků $7 D002448
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a dasatinib $x farmakologie $7 D000069439
- 650 _2
- $a fibronektiny $x metabolismus $7 D005353
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imatinib mesylát $x farmakologie $7 D000068877
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a chronická myeloidní leukemie $x patologie $7 D015464
- 650 _2
- $a fosforylace $x účinky léků $7 D010766
- 650 _2
- $a transport proteinů $x účinky léků $7 D021381
- 650 _2
- $a skupina kinas odvozených od src-genu $x metabolismus $7 D019061
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Röselová, Pavla $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Grebeňová, Dana $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Kuželová, Kateřina $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 9 (2014), s. e107367
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25198091 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20200120155103 $b ABA008
- 999 __
- $a ok $b bmc $g 1102916 $s 924841
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 9 $d e107367 $e 20140908 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20160108